iGluR
Ionotropic glutamate receptors
iGluR (ionotropic glutamate receptor) is a ligand-gated ion channel that is activated by the neurotransmitter glutamate. iGluR are integral membrane proteins compose of four large subunits that form a central ion channel pore. Sequence similarity among all known glutamate receptor subunits, including the AMPA, kainate, NMDA, and δ receptors.
AMPA receptors are the main charge carriers during basal transmission, permitting influx of sodium ions to depolarise the postsynaptic membrane. NMDA receptors are blocked by magnesium ions and therefore only permit ion flux following prior depolarisation. This enables them to act as coincidence detectors for synaptic plasticity. Calcium influx through NMDA receptors leads to persistent modifications in the strength of synaptic transmission.
iGluR Isoform Specific Products
All Product Categories
-
iGluR Inhibitors
(130)
View all products
-
iGluR Agonists
(131)
View all products
-
iGluR Antagonists
(347)
View all products
-
iGluR Activators
(35)
View all products
-
iGluR Modulators
(93)
View all products
-
iGluR MDM2 Inhibitor
(1)
View all products
-
iGluR Controls
(5)
View all products
-
iGluR Ligands
(3)
View all products
-
iGluR Related Products (828)
Related Products (828)
-
Antibodies (11)
-
iGluR Isoform Comparison
-
LBG20304
0 ImagesCat. No.: HY-159584LBG20304 (compound 2s) is a ligand for the homologous GluK5 receptor (IC50: 432 nM), more than 40-fold selective over the homologous GluK1-3 isoforms. Low doses of LBG20304 (<10 μM) have no agonist or antagonist functional response at heterologous GluK2/5 receptors, and at high doses (>10 μM), it exhibits low agonist activity in neuronal slices (rat).
-
NMDA receptor antagonist 11
0 ImagesCat. No.: HY-183201CAS No.: 26727-26-4NMDA receptor antagonist 11 is a NMDA receptor antagonist with an IC50 of 65 μM. NMDA receptor antagonist 11 inhibits glycine action at the NMDA receptor glycine site. NMDA receptor antagonist 11 can be used for research on neurological diseases.
-
(R)-3,4-DCPG
0 ImagesCat. No.: HY-107519CAS No.: 201730-10-1(R)-3,4-DCPG is an AMPA and NMDA antagonist with a Kd of 77 μM for AMPA. (R)-3,4-DCPG complete antagonizes the NMDA-induced depolarization at a concentration of 500 μM. (R)-3,4-DCPG exhibits a weak antagonistic effect on kainate-induced depolarizations.
-
AMPA receptor modulator-4
0 ImagesCat. No.: HY-149975CAS No.: 2917551-59-6AMPA receptor modulator-4, a 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BTD), is an orally active positive allosteric modulator of the AMPA receptors (AMPAR PAMs). AMPA receptor modulator-4 can cross the blood-brain barrier. AMPA receptor modulator-4 increases the cognition performance and improves working memory performance in mice.
-
Felbamate (Standard)
0 ImagesCat. No.: HY-B0184RCAS No.: 25451-15-4Synonyms: W-554 (Standard); ADD-03055 (Standard)Felbamate (Standard) is the analytical standard of Felbamate. This product is intended for research and analytical applications. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
-
SPD-502
0 ImagesCat. No.: HY-15074CAS No.: 245063-59-6Synonyms: NS-1209SPD-502 is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 may be promising for studying neurodegenerative conditions associated with glutamate excitotoxicity.
-
PDZ1 Domain inhibitor peptide TFA
0 ImagesCat. No.: HY-P1195APDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain.
-
L-Glutamic acid-15N,d5
0 ImagesCat. No.: HY-14608S9L-Glutamic acid-15N,d5 is the deuterium and 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
-
(S)-Norzopiclone
0 ImagesCat. No.: HY-U00199ACAS No.: 151776-26-0Synonyms: (S)-N-Desmethyl zopiclone; SEP-174559(S)-Norzopiclone ((S)-N-Desmethyl zopiclone; SEP-174559) is a metabolite of Zopiclone with anxiolytic and anticonvulsant effects. (S)-Norzopiclone has benzodiazepine-like actions at γ2-bearing subtypes of the GABAA receptor and inhibits nACh and NMDA receptors.
-
Indantadol hydrochloride
0 ImagesCat. No.: HY-101440ACAS No.: 202914-18-9Synonyms: CHF-3381Indantadol hydrochloride (CHF-3381) is an orally active, non-selective NMDA antagonist and MAO inhibitor. Indantadol hydrochloride blocks the binding of [³H]-MK-801 to NMDA receptors in a non-competitive manner, with an IC50 of 8.1 μM. Indantadol hydrochloride completely inhibits dopamine release caused by NMDA. Indantadol hydrochloride protects neurons, with an ED₅₀ of 35 μM. Indantadol hydrochloride has anticonvulsant and anti-high pain hypersensitivity activities.
-
Orphenadrine-d3 hydrochloride
0 ImagesCat. No.: HY-B1126SCAS No.: 1309283-23-5Orphenadrine-d3 (hydrochloride) is the deuterium labeled Orphenadrine hydrochloride. Orphenadrine hydrochloride is an orally active and non-competitive NMDA receptor antagonist (crosses the blood-brain barrier) with a Ki of 6.0 μM. Orphenadrine hydrochloride relieves stiffness, pain and discomfort due to muscle strains, sprains or other injuries. Orphenadrine hydrochloride is also used to relieve tremors associated with parkinson's disease. Orphenadrine citrate has good neuroprotective properties, can be used in studies of neurodegenerative diseases.
-
BMS-986169
0 ImagesCat. No.: HY-119886CAS No.: 1801151-08-5BMS-986169 is an inhibitor of the glutamate N-methyl-D-aspartate 2B receptor (GluN2B). BMS-986169 has a high binding affinity for the allosteric regulatory site of the GluN2B subunit, with a Ki value of 4.03-6.3 nM. BMS-986169 can inhibit the function of GluN2B receptors in Xenopus oocytes, with an IC50 value of 24.1 nM. BMS-986169 can also inhibit the activity of the hERG channel, with an IC50 value of 28.4 μM. BMS-986169 can be used in research on treatment-resistant depression.
-
JAMI1001A
0 ImagesCat. No.: HY-124906CAS No.: 1001019-46-0JAMI1001A is a positive allosteric modulator of AMPA receptor. JAMI1001A efficaciously modulates AMPA receptor deactivation and desensitization of both flip and flop receptor isoforms.
-
LY 233536
0 ImagesCat. No.: HY-120189CAS No.: 136845-59-5LY 233536 is a competitive NMDA receptor antagonist.
-
NMDA-IN-2
0 ImagesCat. No.: HY-145897CAS No.: 2761731-14-8NMDA-IN-2 (compound 6b), a Procaine derivative, is a NMDA receptor 2B subtype inhibitor.
-
Tz-IFDL
0 ImagesCat. No.: HY-D3369CAS No.: 3114128-44-5Tz‑IFDL is a chemiluminescent probe for in vivo imaging of N‑methyl‑D‑aspartate receptors (NMDAR), which specifically binds to the NR2B subunit of NMDAR. Tz‑IFDL undergoes a bioorthogonal reaction with probe CL‑NC (HY-D3370), triggering molecular fragment release and chemiluminescence. The CL‑NC/Tz‑IFDL system composed of Tz‑IFDL exhibits a chemiluminescence emission wavelength of 710 nm. When combined with CL‑NC, Tz‑IFDL can be used for deep tissue imaging to distinguish NMDAR expression levels between Alzheimer's disease model mice and normal mice.
-
SGE-301
0 ImagesCat. No.: HY-15787CAS No.: 1427208-12-5SGE-301 is a positive, allosteric NMDAR modulator. SGE-301 recovers NMDAR density and long-term potentiation to normal values. SGE-301 can be used in the research of neurological disorders.
-
trans-ACBD
0 ImagesCat. No.: HY-100616ACAS No.: 117488-23-0Synonyms: trans-1-Aminocyclobutane-1,3-dicarboxylic acidtrans-ACBD (trans-1-Aminocyclobutane-1,3-dicarboxylic acid) is a very potent and selective NMDA receptor agonist that modulates glutamatergic neurotransmission.
-
Neramexane
0 ImagesCat. No.: HY-138973CAS No.: 219810-59-0Neramexane is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.
-
NMDAR antagonist 5
0 ImagesCat. No.: HY-173398CAS No.: 3038464-68-2NMDAR antagonist 5 (Compound A17) is a multi-target antagonist against NMDAR and monoamine transporters (SERT、DAT and NET). NMDAR antagonist 5 shows good NMDAR antagonistic potency (IC50 = 0.3 μM) and monoamine transporter activities (SERT IC50 = 1.1 μM、DAT IC50 = 0.7 μM、NET IC50 = 2.7 μM). NMDAR antagonist 5 is highly safe and has low toxicity (hepatotoxicity and nephrotoxicity (IC50 > 100 μM); cardiotoxicity (IC50 = 24.5 μM)). NMDAR antagonist 5 has antidepressant effects and can be used in the study of depression.
